Ingevity (NYSE:NGVT) Announces Quarterly Earnings Results

Ingevity (NYSE:NGVT) announced its quarterly earnings data on Wednesday. The company reported $1.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.84 by $0.31, Zacks reports. Ingevity had a positive return on equity of 176.88% and a negative net margin of 10.55%.The firm had revenue of $258.00 million for the quarter, compared to analysts’ expectations of $254.73 million. During the same quarter in the prior year, the firm posted $1.01 earnings per share. Ingevity’s revenue for the quarter was up 4.1% compared to the same quarter last year. Ingevity updated its FY 2026 guidance to 4.700-5.200 EPS.

Ingevity Stock Performance

NGVT stock traded up $0.02 on Friday, reaching $74.09. The company’s stock had a trading volume of 164,802 shares, compared to its average volume of 312,121. Ingevity has a 52 week low of $39.74 and a 52 week high of $79.29. The company has a market capitalization of $2.61 billion, a P/E ratio of -20.85 and a beta of 1.24. The firm has a fifty day moving average of $71.20 and a two-hundred day moving average of $64.15. The company has a debt-to-equity ratio of 39.10, a current ratio of 1.33 and a quick ratio of 0.79.

Hedge Funds Weigh In On Ingevity

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Global Retirement Partners LLC bought a new position in Ingevity in the 4th quarter worth approximately $27,000. Meeder Asset Management Inc. bought a new position in Ingevity in the 4th quarter worth approximately $33,000. Geneos Wealth Management Inc. grew its holdings in Ingevity by 85.8% in the 2nd quarter. Geneos Wealth Management Inc. now owns 838 shares of the company’s stock worth $36,000 after buying an additional 387 shares in the last quarter. Headlands Technologies LLC bought a new position in Ingevity in the 2nd quarter worth approximately $46,000. Finally, Kestra Advisory Services LLC bought a new position in Ingevity in the 4th quarter worth approximately $47,000. 91.59% of the stock is owned by institutional investors.

Analyst Ratings Changes

NGVT has been the topic of several research reports. Wells Fargo & Company upped their price objective on Ingevity from $65.00 to $75.00 and gave the company an “equal weight” rating in a research note on Friday, February 27th. Weiss Ratings restated a “sell (d-)” rating on shares of Ingevity in a research note on Tuesday, April 21st. Wall Street Zen cut Ingevity from a “buy” rating to a “hold” rating in a research note on Saturday, April 4th. Jefferies Financial Group reiterated a “buy” rating and set a $82.00 price target on shares of Ingevity in a research report on Thursday, February 26th. Finally, BMO Capital Markets reiterated an “outperform” rating and set a $83.00 price target on shares of Ingevity in a research report on Monday, March 2nd. Two equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Ingevity currently has an average rating of “Hold” and an average target price of $80.00.

Ingevity Company Profile

Ingevity Corporation, traded as NGVT, is a specialty chemicals and performance materials company headquartered in North Charleston, South Carolina. The company operates two primary business units: Performance Chemicals and Performance Materials. The Performance Chemicals segment produces and markets specialty chemicals derived largely from wood and other natural feedstocks, including rosin acids, tall oil fatty acids and esters, as well as specialty petroleum resins. These products serve a broad range of industries, including paper, adhesives, coatings, oilfield drilling and consumer goods.

The Performance Materials segment develops and manufactures activated carbon products and composites for applications such as automotive emissions control, industrial air and water purification, and spill containment.